The ABPI have welcomed the announcement of the appointment of Kristen McLeod as new Director for the Office of Life Sciences (OLS), effective 13 November 2017.
Kristen replaces former OLS Director Nicole Mather, who was appointed Director of the newly created OLS in April 2014.
Mike Thompson, Chief Executive of The ABPI welcomed Kristen's appointment and thanked Nicole for her work:
“As the body responsible for advocating our industry’s priorities in Government, I would like to formally welcome Kristen McLeod to her new post as Director of the OLS.
"We have a real opportunity to create an environment for Britain to be one of the best places in the world for discovering, developing and adopting the very best of modern medicine - Kristen’s expertise and experience at the heart of health policymaking provides fresh impetus to this effort.
"I look forward to working with Kristen and her team to build upon the ABPI’s and the pharmaceutical industry’s close working relationship with the OLS; an organisation that has been led and championed for the past three-and-a-half years by Nicole Mather.
"From the development and launch of the Accelerated Access Review in 2015 to the new Life Sciences Industrial Strategy announced in August this year, Nicole has played a critical role in leading the growth, expansion and the increasing influence of the Life Sciences industry in the UK. Furthermore, she has been instrumental in raising the importance and impact of our industry on the health and wealth of the population across government departments as the country prepares for Brexit. Her passion and commitment to the sector, her support in encouraging increased joint working with the NHS and her success in helping secure Government investment for medicines manufacturing in this country has created a solid foundation on which to build. We would like to wish her every success in the future.”
Read the annoucement from the Office of Life Sciences.
## ENDS ##
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone (24hrs): +44 (0) 20 7747 7147
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.